Controlled study of the effects of continuous intrathecal baclofen infusion in non-ambulant children with cerebral palsy

Developmental Medicine and Child Neurology

Volumn 53, Issue 8, 2011, Pages 736-741

  Morton, Richard E ^a   Gray, Natalie ^b   Vloeberghs, Michael ^b  

^a DERBYSHIRE CHILDREN S HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; DIAZEPAM;

ADOLESCENT; ARTICLE; ASHWORTH SCORE; CAREGIVER QUESTIONNAIRE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DECUBITUS; FEMALE; FUNCTIONAL ASSESSMENT; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM; HEALTH CARE COST; HUMAN; LETHARGY; MALE; PATIENT CARE; PEDIATRIC EVALUATION OF DISABILITY INVENTORY; PENN SPASM SCORE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SPASTIC CEREBRAL PALSY; STRUCTURED QUESTIONNAIRE; SWALLOWING; TREATMENT OUTCOME; URINE RETENTION;

ADOLESCENT; ANALYSIS OF VARIANCE; BACLOFEN; CASE-CONTROL STUDIES; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; MALE; MUSCLE RELAXANTS, CENTRAL; QUESTIONNAIRES; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960094027     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2011.04009.x     Document Type: Article

References (28)

1. Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985; 2: 125-7.
2. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270: 2475-7.
3. Armstrong RW, Steinbok P, Cochrane DD, Kube RN, Fife SE, Farrell K. Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. J Neurosurg 1997; 87: 409-14.
4. Ordia JI, Fischer E, Adamski E. Chronic intrathecal delivery of baclofen by programmable pump for the treatment of severe spasticity. J Neurosurg 1996; 85: 452-7.
5. Middel B, Kuipers-Upmeijer H, Bouma J, et al. Effects of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997; 63: 204-9.
6. Becker R, Alberti O, Bauer B. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol 1997; 244: 160-6.
7. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996; 11: 77-83.
8. Vloeberghs M, Cartmill M, Bass S. The use of intrathecal baclofen in the management of spasticity in children with cerebral palsy. Br J Neurosurg 2001; 15: 546-56.
9. Butler C, Campbell S. AACPDM Treatment Outcomes Committee Review Panel. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. Dev Med Child Neurol 2000; 42: 634-45.
10. Sampson FC, Hayward A, Evans G, et al. The effectiveness of intrathecal baclofen in the management of patients with severe spasticity. Sheffield: Trent Institute for Health Services Research, Universities of Leicester, Nottingham, and Sheffield, Guidance Note for Purchasers 2000, 00/01.
11. Haley S, Coster W, Ludlow L, et al. Pediatric Evaluation of Disability Inventory (PEDI). Development, standardisation and administration manual 1992. New England Medical Centre Hospitals: Boston PEDI research group.
12. Gray N, Morton RE, Vloeburghs M. Goals and outcomes of continuous intrathecal baclofen in children with severe spastic cerebral palsy. Eur J Paediatr Neurol (Forthcoming).
13. Evans P, Johnson A, Mutch L, Alberman E. A standardised form for recording clinical findings in children with a motor deficit of central origin. Dev Med Child Neurol 1989; 31: 119-20.
14. Bohannon RW, Smith MB. Inter rater reliability of a modified scale of muscle spasticity. Phys Ther 1987; 67: 206-7.
15. Penn RD, Savoy SM, Corcos DC, Latash M, Gottlieb G. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517-8.
16. Russell D, Rosenbaum P, Gowland C, et al. GMFM Gross Motor Function Measure. Hamilton, Ontario: Hugh MacMillan Rehabilitation Centre, McMaster University, 1990.
17. Schneider JW, Gurucharri LM, Gutierrez AI, Gaebler-Spira DJ. Health-related quality of life and functional outcome measures for children with cerebral palsy. Dev Med Child Neurol 2001; 43: 601-8.
18. Mackie PC, Jessen EC, Jarvis SN. The Lifestyle Assessment Questionnaire; an instrument to measure the impact of disability on the lives of children with cerebral palsy and their families. Child Care Health Dev 1998; 24: 473-86.
19. Rosenbaum P. The randomised controlled trial: an excellent design, but can it address the big questions in neurodisability? Dev Med Child Neurol 2010; 52: 111. (Editorial).
20. Hoving MA, Van Raak E, Spincemaille G, Palmans L, Becher J, Vles J. Efficacy of intrathecal baclofen in children with intractable spastic cerebral palsy: a randomised controlled trial. Eur J Paediatr Neurol 2009; 13: 240-6.
21. Campbell WM, Ferrel A, McLaughlin JF, et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol 2002; 44: 660-5.
22. Awaad Y, Tayem H, Munoz S, Ham S, Michon AM, Awaad R. Functional assessment following intrathecal baclofen therapy in children with spastic cerebral palsy. J Child Neurol 2003; 18: 26-34.
23. Krach L, Kriel R, Gilmartin R, et al. GMFM 1year after continuous intrathecal baclofen infusion. Pediatr Rehabil 2005; 8: 207-13.
24. Gooch J, Oberg W, Grams B, Ward L, Walker M. Care provider assessment of intrathecal baclofen in children. Dev Med Child Neurol 2004; 46: 548-52.
25. Narayanan UG, Fehlings D, Weir S, Knights S, Kiran S, Campbell K. Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Dev Med Child Neurol 2006; 48: 804-12.
26. Colver A. Quality of life and participation. Dev Med Child Neurol 2009; 51: 656-9.
27. World Health Organization. International Classification of Functioning, Disability and Health (ICF). Geneva: World Health Organization, 2001.
28. Sampson FC, Haywood A, Evans G, Morton R, Collett B. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. J Neurosurg 2002; 96: 1052-7.